文献速递流行病学与生物统计临床试验与 GCP

前列腺特异性抗原筛查与15年前列腺癌死亡率:CAP随机临床试验的二次分析

Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.
PubMed 文献 · JAMA · 2024-01-01

该研究为CAP随机临床试验的二次分析,纳入英格兰和威尔士573家初级保健机构中50至69岁男性,比较单次邀请PSA筛查与不邀请筛查对15年前列腺癌死亡率的影响。中位随访15年时,干预组前列腺癌死亡率为0.69%,对照组为0.78%(RR 0.92,95%CI 0.85-0.99;P=0.03),绝对死亡减少幅度较小。

要点

  • 单次邀请PSA筛查组15年前列腺癌死亡率为0.69%,对照组为0.78%(RR 0.92,95%CI 0.85-0.99;P=0.03)。
  • 筛查增加低级别(GS≤6:2.2% vs 1.6%)和局限期(T1/T2:3.6% vs 3.1%)前列腺癌检出,但未增加中高级别或晚期肿瘤检出。
  • 全因死亡率两组无显著差异(干预组23.2% vs 对照组23.3%;RR 0.97,95%CI 0.94-1.01;P=0.11)。

核心结论

  • 在中位随访15年时,与不进行常规筛查的标准实践相比,单次邀请PSA筛查降低了前列腺癌死亡数,但绝对死亡减少幅度较小。

研究设计与样本

  • CAP随机临床试验的二次分析,纳入英格兰和威尔士573家初级保健机构中50至69岁男性,机构于2001年9月25日至2007年8月24日随机分组,男性于2002年1月8日至2009年1月20日入组,随访于2021年3月31日完成。

主要发现

  • 干预组1199例(0.69%,95%CI 0.65%-0.73%)死于前列腺癌,对照组1451例(0.78%,95%CI 0.73%-0.82%)(RR 0.92,95%CI 0.85-0.99;P=0.03)。
  • 干预组前列腺癌诊断12013例,对照组12958例,15年累积风险分别为7.08%(95%CI 6.95%-7.21%)和6.94%(95%CI 6.82%-7.06%)。
  • 与对照组相比,PSA筛查干预增加了低级别(GS≤6:2.2% vs 1.6%;P<0.001)和局限期(T1/T2:3.6% vs 3.1%;P<0.001)疾病的检出,但未增加中级别(GS为7)、高级别(GS≥8)、局部晚期(T3)或远处晚期(T4/N1/M1)肿瘤的检出。
  • 干预组全因死亡45084例(23.2%,95%CI 23.0%-23.4%),对照组50336例(23.3%,95%CI 23.1%-23.5%)(RR 0.97,95%CI 0.94-1.01;P=0.11)。
  • 干预组8例(0.7%)和对照组7例(0.5%)前列腺癌死亡与诊断性活检或前列腺癌治疗相关。

关键数值与推荐

  • 干预组男性接受单次PSA筛查邀请,若PSA水平≥3.0 ng/mL则进行后续诊断性检查;对照组接受标准实践(不邀请筛查)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP) reported no effect of prostate-specific antigen (PSA) screening on prostate cancer mortality at a median 10-year follow-up (primary outcome), but the long-term effects of PSA screening on prostate cancer mortality remain unclear. OBJECTIVE: To evaluate the effect of a single invitation for PSA screening on prostate cancer-specific mortality at a median 15-year follow-up compared with no invitation for screening. DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis of the CAP randomized clinical trial included men aged 50 to 69 years identified at 573 primary care practices in England and Wales. Primary care practices were randomized between September 25, 2001, and August 24, 2007, and men were enrolled between January 8, 2002, and January 20, 2009. Follow-up was completed on March 31, 2021. INTERVENTION: Men received a single invitation for a PSA screening test with subsequent diagnostic tests if the PSA level was 3.0 ng/mL or higher. The control group received standard practice (no invitation). MAIN OUTCOMES AND MEASURES: The primary outcome was reported previously. Of 8 prespecified secondary outcomes, results of 4 were reported previously. The 4 remaining prespecified secondary outcomes at 15-year follow-up were prostate cancer-specific mortality, all-cause mortality, and prostate cancer stage and Gleason grade at diagnosis. RESULTS: Of 415 357 eligible men (mean [SD] age, 59.0 [5.6] years), 98% were included in these analyses. Overall, 12 013 and 12 958 men with a prostate cancer diagnosis were in the intervention and control groups, respectively (15-year cumulative risk, 7.08% [95% CI, 6.95%-7.21%] and 6.94% [95% CI, 6.82%-7.06%], respectively). At a median 15-year follow-up, 1199 men in the intervention group (0.69% [95% CI, 0.65%-0.73%]) and 1451 men in the control group (0.78% [95% CI, 0.73%-0.82%]) died of prostate cancer (rate ratio [RR], 0.92 [95% CI, 0.85-0.99]; P = .03). Compared with the control, the PSA screening intervention increased detection of low-grade (Gleason score [GS] ≤6: 2.2% vs 1.6%; P < .001) and localized (T1/T2: 3.6% vs 3.1%; P < .001) disease but not intermediate (GS of 7), high-grade (GS ≥8), locally advanced (T3), or distally advanced (T4/N1/M1) tumors. There were 45 084 all-cause deaths in the intervention group (23.2% [95% CI, 23.0%-23.4%]) and 50 336 deaths in the control group (23.3% [95% CI, 23.1%-23.5%]) (RR, 0.97 [95% CI, 0.94-1.01]; P = .11). Eight of the prostate cancer deaths in the intervention group (0.7%) and 7 deaths in the control group (0.5%) were related to a diagnostic biopsy or prostate cancer treatment. CONCLUSIONS AND RELEVANCE: In this secondary analysis of a randomized clinical trial, a single invitation for PSA screening compared with standard practice without routine screening reduced prostate cancer deaths at a median follow-up of 15 years. However, the absolute reduction in deaths was small. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN92187251.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Martin RM, Turner EL, Young GJ, et al. Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial. JAMA. 2024. PMID: 38581198. doi:10.1001/jama.2024.4011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。